company

Boehringer Ingelheim

as of 2026-07-01
Monitor thisAsk about this
at a glance
18 trials sponsored · 19 assets in the graph
Synthesized from structured facts only — each point cited above.

Financials

SEC EDGAR XBRL · latest period per metric
No financials loaded for this company (may be non-US-listed — recorded as a gap, not faked).

Pipeline

19 assets
BI 409306BI 409306 10 mg QDBI 409306 100 mg QDBI 409306 25 mgBI 409306 50 mgBI 425809BI 425809 dose 1BI 425809 dose 2BI 425809 dose 3BI 425809 dose 4BI 498306 25 mg QDBI 498306 50 mg QDCT-155CT-156CT-156-C-001Clinical Learning Study smartphone app (i.e., the study app)Digital therapeutic (CT-155)IclepertinStudy App

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
asset
BI 409306
small molecule
drug
BI 409306 10 mg QD
small molecule
drug
BI 409306 100 mg QD
small molecule
drug
BI 409306 25 mg
small molecule
drug
BI 409306 50 mg
small molecule
drug
BI 425809
small molecule
drug
BI 425809 dose 1
small molecule
drug
BI 425809 dose 2
small molecule
drug